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ABSTRACT
Background and Objectives: Reports on the incidence of intracardiac thrombi (ICT) have increased over the last few de-
cades, but ICT are still relatively rare among children. Left ventricular systolic dysfunction and dilatation may contribute to the 
formation of ICT, especially when a hypercoagulable state exists. The aim of this study was to describe the incidence of ICT 
in children suffering from cardiac failure with left ventricular dysfunction and to identify risk factors on admission for devel-
oping ICT. Subjects and Methods: We conducted a retrospective chart review of children up to 18 years of age admitted to 
the Pediatric Intensive Care Unit due to cardiac failure with left ventricular dysfunction between January 1, 2003 and Decem-
ber 31, 2008. Results: Twenty-one patients were admitted with clinical signs of cardiac failure and echocardiographic find-
ings compatible with dilated cardiomyopathy or acute myocarditis. Dilated cardiomyopathy was diagnosed in 11 patients (52%). 
Adenoviruses and enteroviruses were suspected to be the cause of acute myocarditis in 5 cases. The personal or family history 
of hypercoagulable states were obtained from 19 out of 21 patients (90%). Among patients with a hypercoagulable state, 3 out 
of 7 developed ICT compared with none out of 12 among patients without hypercoagulability (p=0.043). Two of these 3 pa-
tients experienced an embolic event. Conclusion: Cardiac failure with left ventricular dysfunction may predispose the patient 
to ICT and increase the risk of thromboembolism, especially when an underlying hypercoagulable state exists. The hyperco-
agulable state must be carefully evaluated on admission in these patients. (Korean Circ J 2011;41:453-457)
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Introduction
Intracardiac thrombi (ICT) are relatively rare among chil-
dren. Reports on the incidence of ICT have increased in the 
last few decades, especially when a hypercoagulable state ex-
ists.
1-5) Left ventricular systolic dysfunction and dilatation may 
contribute to the formation of ICT by altering the hemostatic 
state with concomitant blood stasis within a dilated left ven-
tricle. Furthermore, heart failure is associated with abnormali-
ties of endothelial function.
6-8) In patients with congenital he-
art diseases, causes of ICT may differ, depending on the ch-
amber of the heart involved. 
Thrombi of the right side are usually associated with the 
presence of central venous catheters, endocarditis and poly-
cythemia,
9)10) while dilated cardiomyopathy, atrial fibrillation, 
endocarditis, prosthetic heart valves, intracardiac tumors 
and rheumatic mitral stenosis are the most important pre-
disposing factors for cardiac emboli sources when the left 
chamber is involved. A significant complication of ICT is the 
development of cerebral thrombosis.
11) Recently, reports of 
ICT as an important cause of mortality in post-Fontan pro-
cedure patients are increasing.
12) 
We hereby present our experience in pediatric patients 
who presented with clinical cardiac failure due to acute myo-
carditis or dilated cardiomyopathy and developed secondary 
complications of the left ventricular thrombi. 454   Thrombiphilia and Intracardiac Thrombi 
Subjects and Methods
This study was approved by the Institutional Review Board 
of our Medical Center. We retrospectively reviewed the medi-
cal records of all patients up to 18 years of age admitted to the 
seven-bed pediatric intensive care unit (PICU) of a general hos-
pital from January 1, 2003 to December 31, 2008 due to acute 
myocarditis or dilated cardiomyopathy accompanied by a low 
systolic ejection fraction of below 40%. Patients were identifi-
ed using the hospital computerized database. Those in a state 
of pre-shock or shock due to non cardiogenic causes were ex-
cluded.
All pediatric patients with clinical signs of left heart failure, 
an enlarged heart shadow on chest radiographs, and left ven-
tricular dysfunction with an ejection fraction below 40% on 
two-dimensional echocardiography as measured by Simp-
son’s method
13) were included. The selection of a 40% ejec-
tion fraction was based on the American Society of Echocar-
diography guidelines that define an abnormal ejection frac-
tion as <55%, with the cutoffs for moderately abnormal and 
severely abnormal at 44% and 30%, respectively.
14) The diag-
nosis of dilated cardiomyopathy was based on definitions and 
classifications of cardiomyopathies by the American Heart 
Association in 2006, ventricular chamber enlargement and 
systolic dysfunction with normal left ventricle wall thickness, 
as determined by two-dimensional echocardiography.
15) Gr-
ading of mitral regurgitation was estimated by color flow Do-
ppler echocardiography. Acute myocarditis was diagnosed 
on the basis of clinical and laboratory results. Polymerase 
chain reaction (PCR) of nasopharyngeal and rectal swabs was 
performed in patients with a history of acute viral disease 
that preceded cardiac failure such as upper respiratory tract 
infection, diarrhea and fever.
Thrombophilia workup including prothrombin time, acti-
vated partial thromboplastin, protein C, protein S, antithrom-
bin III, activated protein C resistance, thrombophilic muta-
tions of factor V Leiden and thermolabile methylenetetrahy-
drofolate reductase (MTHFR C677T), prothrombin G20210A, 
antiphospholipid antibodies and plasma level of homocyste-
ine was performed in the 3 patients that developed ICT.
Data was extracted on patient demographics, mode of 
presentation, clinical features, investigation on admission, in-
patient management and follow up. Patients with ICT were 
characterized and compared to the rest of the group. The in-
cidence of ICT in patients with and without hypercoagula-
bility was compared by the Fisher Exact test. 
Results
Twenty-one patients were admitted to the PICU due to car-
diac failure with acute myocarditis or dilated cardiomyopathy. 
All patients had clinical signs of cardiac failure on admission. 
A chest X-ray revealed a cardiac shadow enlargement in all the 
participants and signs of lung congestion in 17 patients (81%). 
The characteristics of the patients are summarized in Table 1. 
Anamnesis details of a personal or family history predispos-
ing the patient to hypercoagulability were obtained in 19 pa-
tients (90%). All patients underwent echocardiography wi-
thin 24 hours of admission, which revealed heart enlarge-
ment, varying degrees of mitral regurgitation and a decreas-
ed ejection fraction. Echocardiography was repeated at in-
tervals of 48 to 96 hours. Dilated cardiomyopathy was diag-
nosed in 11 (52%) patients. Adenoviruses and enteroviruses 
were suspected to be the cause of acute myocarditis in 5 cases. 
A family history of thrombophilia was found in 5 patients 
(deep vein thrombosis, stroke, recurrent abortions), and a per-
sonal high risk for a hypercoagulable state was found in 2 pa-
tients (signet cell carcinoma, long flight). Within 24 hours of 
admission, low-molecular-weight heparin (LMWH) was ad-
ministered in 14 patients (66%). All patients with a personal 
or familial high risk of thrombophilia were treated with LM-
WH on admission. 
According to our policy, every child admitted with moder-
ate to severe left ventricle dysfunction was treated with LM-
WH. Some of the patients were not treated with LMWH due 
to lack of awareness of the care team.
ICT were observed in 3 (14%) patients, all of whom had 
sinus rhythm. Among the patients with a hypercoagulable 
state, 3 out of 7 developed ICT compared with none out of 12 
Table 1. Characteristics of the admitted children suffering from 
cardiac failure with left ventricular dilation
Patients 21
Age (years) 3.6 (range 0.1-17)
Gender (male/female) 9/12
Idiopathic dilated cardiomyopathy
  (including familial)
11
Suspected viral-induced acute 
  myocarditis
05
Genetic metabolic disorders 02
Duchenne myopathy 01
Anomalous origin of left 
  coronary artery
01
Toxic cardiomyopathy 01
Ejection fraction below 40% 18 (range 15–28)
Mitral regurgitation
Mild-4 patients
Moderate-12 patients
Severe-5 patients
Low-molecular-weight heparin 
  prophylaxis (%)
.14 (66)
Family or personal history predisposing 
  to hypercoagulability (%) 
7/19 (36.8)
Intracardiac thrombi (%) 0.3 (14)Ibrahim Abu-Kishk, et al.   455
among patients without hypercoagulability (p=0.043). The 
characteristics of the patients with ICT are summarized in 
Table 2. 
Patient No. 1 (Table 2) had a family history of stroke and 
was treated with LMWH within 24 hours of admission as a 
prophylactic dose, but developed ICT 48 hours later. Work 
up for thrombophilia revealed the MTHFR C677T mutation. 
Patient No. 2 (Table 2) was also treated with LMWH within 
24 hours of admission as a prophylactic dose, due to a hyper-
coagulable state (signet cell carcinoma), but developed ICT 
on day 5 after admission during a chemotherapy course of 
5-fluorouracil (5-FU). When the treatment with 5-FU was 
stopped, rapid cardiac improvement occurred. Work up for 
thrombophilia revealed heterozygosity for the MTHFR 
C677T mutation. Patient No. 3 (Table 2) had a known dilat-
ed cardiomyopathy that had been controlled by conservative 
medication for a period of 9 months. One week prior to ad-
mission, she stopped taking her medication and flew from 
Peru to Israel. This patient already had ICT on admission that 
probably developed after a long-haul flight from Peru to Is-
rael.
24) Thrombophilia work up revealed normal results. Two 
of these patients developed embolic events, 1 of them in-
volving the brain. The mean ejection fraction was 18.6% in pa-
tients with ICT compared with 18% in patients without ICT. 
Five patients required mechanical ventilation on admis-
sion, and 3 of them deceased (signet cell carcinoma, mito-
chondrial disease, and very long chain acyl-CoA dehydroge-
nase deficiency). All 21 patients were followed up for a me-
dian period of 14 months (range of 29 months) and in 3 of 
these patients normal heart function was restored with sus-
pected acute myocarditis. 
Of the 5 patients with a positive familial history of hyper-
coagulability, 1 suffered from suspected acute myocarditis due 
to enterovirus, 1 suffered from anomalous origin of coro-
nary artery (AOCA) and the other 3 had idiopathic dilated 
cardiomyopathy. Four of them were treated with LMWH on 
admission (AOCA excluded). Heart function was complete-
ly restored in the patient with acute myocarditis, improved 
significantly in the patient with AOCA and remained poor in 
the rest. 
Discussion
In a cohort of 21 pediatric patients admitted for acute myo-
carditis or dilated cardiomyopathy with a significant decre-
ase in ejection fraction, 3 (14%) suffered from ICT. A similar 
incidence (14%) was reported by Günthard et al.
16) when de-
scribing 130 pediatric patients with dilated cardiomyopathy. 
In this series, patients with ICT had a seriously impaired 
fractional shortening (10±3%) as compared to those with-
out thromboembolism (17±6%). Contrary to these findings, 
we did not find significant differences in ejection fraction be-
tween patients who did or did not develop ICT. 
A personal or family predisposition to hypercoagulability 
was identified in 36.8% of the participants and in all patients 
with ICT. This finding may help to identify patients that are 
likely to develop ICT. The association between ICT and a hy-
percoagulability state is in agreement with previous studies 
on pediatric populations that focused on hypercoagulability 
states as a predisposing factor for the formation of ICT.
5)6)17)18) 
A retrospective study was conducted that analyzed the fea-
tures and risk factors of childhood thrombotic events in 59 
patients with cardiac defects. Cardiomyopathy was found to 
be one of the risk factors for developing ICT, and 23 of the 59 
Table 2. Characteristics of the 3 patients who developed intracardiac thrombi
Characteristic Patient 1 Patient 2 Patient 3
Age (years) 2.5 17 15
Gender Female Male Female
Background Healthy Signet-ring cell carcinoma Dilated cardiomyopathy
Etiology for cardiomyopathy Viral adenovirus Toxic due to 5-fluorouracil treatment Familial
Ejection fraction below 40% 20 20 16
Mitral regurgitation Moderate  Moderate  Moderate 
Thrombi Left ventricle Left ventricle+right atrium Left ventricle
Family or personal history 
  predisposing to hypercoagulability 
Yes Yes Yes
Anticoagulation treatment Enoxaparin Enoxaparin Enoxaparin
Embolic event Right hemiparesis Infarct distal right thumb Non-embolic events
Predisposition to hypercoagulability
Homozygous MTHFR C677T 
  mutation
Malignancy Long-haul flight
Outcome
Mild right hemiparesis
Cardiac improvement-EF 45%
Decreased
  (metastatic carcinoma)
Cardiac improvement
EF 50%
MTHFR: methylenetetrahydrofolate reductase, EF: ejection fraction456   Thrombiphilia and Intracardiac Thrombi 
described patients had at least one thrombophilic mutation.
19) 
In the current study, Patient No. 1 (Table 2) had a family 
history of stroke and was treated with LMWH as a prophy-
lactic dose, but developed ICT. Work up for thrombophilia 
revealed the MTHFR C677T mutation. Patient No. 2 (Table 2) 
was also treated with LMWH, due to a hypercoagulable state 
(signet cell carcinoma), but developed ICT during a chemo-
therapy course of 5-FU. When the treatment with 5-FU was 
stopped, rapid cardiac improvement occurred. Work up for th-
rombophilia revealed heterozygosity for the MTHFR C677T 
mutation. 
In the literature, 5-FU therapy in combination with other 
chemotherapy drugs was found to be a possible cause of an-
gina, dysrhythmias and dilated cardiomyopathy. In some cas-
es, the pathological findings were compatible with acute myo-
carditis or toxic myopathy.
20-23) Cancer is one of the most im-
portant acquired risk factors for the development of throm-
boembolism. Tumors can express procoagulant proteins and 
may induce the production of inflammatory cytokines that in-
directly contribute to the development of hypercoagulability.
24) 
Patient No. 3 (Table 2) had a known dilated cardiomyopa-
thy that had been controlled by conservative medications for 
a period of 9 months. One week prior to admission, the pa-
tient stopped taking her medication and flew from Peru to 
Israel. A long-haul flight is a risk factor that may activate the 
coagulation system.
25)
Results of several adult studies regarding the degree of mi-
tral regurgitation and ICT formation suggest that severe mi-
tral regurgitation in patients with ventricular dysfunction pre-
vents left ventricular thrombus formation by decreasing stasis 
and sluggish blood flow.
26) In the current study, all the patients 
had mitral regurgitation, but none of the 3 patients that de-
veloped ICT had severe mitral regurgitation. 
It is recommended to treat adult patients with dilated car-
diomyopathy who are considered to be at high risk for throm-
boembolism with prophylactic anticoagulants.
27) In the pedi-
atric population, there is no apparent evidence to support 
prophylactic anticoagulant treatment of patients with dilated 
cardiomyopathy. However, there is a recommendation for the 
routine use of anticoagulants in children with poor ventricu-
lar function within the context of dilated cardiomyopathy.
16)
Unfractionated heparin or LMWH is usually the recom-
mended anti-thrombotic therapy, unless there is a major ves-
sel occlusion causing critical compromise of organs or limbs.
28) 
In the current study, ICT developed despite prophylactic ad-
ministration of LMWH on admission and regardless of the 
degree of the ejection fraction, which was similar in both gr-
oups. This emphasizes the necessity for repeated echocardio-
graphs even when LMWH is administered, especially when 
a personal or familial hypercoagulable state coexists. It is un-
clear whether or not more aggressive anti-coagulation treat-
ment could have prevented the thromboembolic events. 
Limitations
This study is limited by its retrospective nature, the small 
group of patients and the fact that thrombophilia work up 
was not performed in all participants. Furthermore, no con-
sistent policy to prevent the formation of ICT was used in all 
participants and history details regarding a personal or fami-
lial history of hypercoagulability were missing in 2 patients. 
With the knowledge of these limitations, unequivocal conclu-
sions cannot be reached, but we suggest taking note of specific 
details about personal and familial hypercoagulable states. 
Patients with a higher risk for developing ICT must be fol-
lowed carefully when presenting with left ventricle dysfunc-
tion even when prophylactic anti-coagulation treatment has 
been administered. We also suggest considering thrombo-
philia work-up in patients with dilated cardiomyopathy and 
left ventricle dysfunction. Further studies are needed to de-
termine the optimal LMWH dosage in similar cases.
Conclusion
Our data suggests that an underlying hypercoagulable 
state may be a significant risk factor for ICT in pediatric pa-
tients with left ventricular dysfunction. On admission, a hy-
percoagulable state needs to be carefully evaluated and appro-
priate treatment should be initiated. 
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